Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

3(30%)

Results Posted

50%(2 trials)

Phase Distribution

Ph not_applicable

30%

Ph phase_1

10%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

1(12.5%)

Phase 2Efficacy & side effects

4(50.0%)

N/ANon-phased studies

3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(6)

Completed(4)

Detailed Status

Completed4

Recruiting3

Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (12.5%)

Phase 24 (50.0%)

N/A3 (37.5%)

Trials by Status

recruiting330%

completed440%

not_yet_recruiting330%

Recent Activity

3 active trials

Showing 5 of 10

completedphase_2

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

NCT03472586

not_yet_recruitingphase_2

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

NCT07612007

recruitingphase_1

Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment

NCT06611007

not_yet_recruitingnot_applicable

Embolization of Ovarian Vein and Pelvic Venous Reservoir for Treatment of Secondary Pelvic Congestion Syndrome

NCT07472504

recruitingnot_applicable

Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200

NCT06930677

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT03472586Phase 2

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Completed

NCT07612007Phase 2

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Not Yet Recruiting

NCT06611007Phase 1

Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment

Recruiting

NCT07472504Not Applicable

Embolization of Ovarian Vein and Pelvic Venous Reservoir for Treatment of Secondary Pelvic Congestion Syndrome

Not Yet Recruiting

NCT06930677Not Applicable

Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200

Recruiting

NCT07206342Not Applicable

Evaluation of the Non-inferiority of Resorbable Gelatin Embolization Compared to Embolization Combined With Endometrial Aspiration for the Management of Hemorrhagic Uterine Vascular Abnormalities Following Premature Termination of Pregnancy

Not Yet Recruiting

NCT06945887

Treatment of Desmoid Fibromatosis With Arterial Embolization

Recruiting

NCT06595264

Vein of Galen Aneurysm

Completed

NCT00335829Phase 2

Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Completed

NCT00028626Phase 2

Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer